New pain block could cut opioid use after lung transplants

NCT ID NCT07641647

Not yet recruiting Symptom relief Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a long-acting form of the numbing drug bupivacaine (liposomal bupivacaine) can reduce pain and the need for strong opioid painkillers after lung transplant surgery. 88 adults receiving a double lung transplant will get an intercostal nerve block either with or without the liposomal version. Researchers will measure pain scores and opioid use for 72 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal bupivacaine
What this could lead to: If it works, this could provide better pain relief and reduce the need for opioids after lung transplant surgery.
What could go wrong: This is a small, early-stage trial (88 people) testing a pain management technique, not a cure. The benefit may be modest or not statistically significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIPOSOMAL BUPIVACAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOSOMAL BUPIVACAINE LUNG TRANSPLANTATION PAIN MANAGEMENT

Contacts and locations

Locations

The Second Affiliated Hospital of Zhejiang University anesthesiology department

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.